China Biosimilars Market Size, Industry Share And Growth in 2018
The global Biosimilars market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Get free request sample @ https://www.radiantinsights.com/research/china-biosimilars-industry-2018/request-sample?utm_source=Anurag&utm_campaign=Sharma
China plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of xx%.
This report studies the Biosimilars development status and future trend in China, focuses on top players in China, also splits Biosimilars by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.
The major players in China market include
Pfizer
Sandoz International GmbH
Teva Pharmaceuticals Industries
Amgen Inc
Biocon
Dr. Reddy's Laboratories
F. Hoffmann-La Roche
Celltrion
Samsung Bioepis
Geographically, this report splits the China market into six regions,
South China
East China
Southwest China
Northeast China
North China
Central China
Northwest China
On the basis of product, this report displays the sales volume (K MT), revenue (Million USD), product price (USD/MT), market share and growth rate of each type, primarily split into
Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)
Peptides (Glucagon, Calcitonin)
Browse full report with TOC @ https://www.radiantinsights.com/research/china-biosimilars-industry-2018?utm_source=Anurag&utm_campaign=Sharma
On the basis of the end users/application, this report covers
Oncology
Blood Disorders
Comments
Post a Comment